Course of Treatment of Chronic Bleeding and Anemia with Systemic Bevacizumab Treatment in Hereditary Hemorrhagic Telangiectasia: A Retrospective Cohort

Basit Öğe Kaydı
dc.authorscopusid58669948100
dc.authorscopusid56979868700
dc.authorscopusid57192253317
dc.contributor.authorDurak E.
dc.contributor.authorUğur M.C.
dc.contributor.authorGediz F.
dc.date.accessioned2024-03-09T19:40:08Z
dc.date.available2024-03-09T19:40:08Z
dc.date.issued2023
dc.departmentİzmir Bakırçay Üniversitesien_US
dc.description.abstractObjective: Hereditary hemorrhagic telangiectasia (HHT), is an autosomal dominant disorder that causes abnormal angiogenesis. Interest in targeted therapies has been increasing in recent years, especially for the treatment of severe forms of HHT. One of these treatment options is the vascular endothelial growth factor inhibitor bevacizumab. Purpose of this study is to investigate the effect of systemic bevacizumab use on the treatment of chronic bleeding course and anemia in patients diagnosed with HHT. Material and Methods: The treatment response and adverse events of patients with bevacizumab were evaluated retrospectively. Results: The mean age was 51,5. Mean duration of treatment was 15.4 (4-25 months) months. The first 4 doses of 5 mg/kg intravenous bevacizumab were administered at 2-week intervals in all patients. Bevacizumab maintenance continued at a dose of 5 mg/kg in monthly periods. With bevacizumab treatment, an increase in hemoglobin values, a decrease in epistaxis severity score, parenteral iron and erythrocyte transfusion requirement were achieved. Side effects observed were allergic rash in one patient and arthralgia in one patient. None of the patients required discontinuation of treatment due to side effects. Conclusion: Bevacizumab is a promising treatment option in HHT, which can be mortal if not controlled. However, there remains a need for more comprehensive studies in order to achieve a global consensus on treatment protocols and management of adverse events. © 2023 by Türkiye Klinikleri.en_US
dc.identifier.doi10.5336/medsci.2023-96203
dc.identifier.endpage286en_US
dc.identifier.issn1300-0292
dc.identifier.issue3en_US
dc.identifier.scopus2-s2.0-85175162078en_US
dc.identifier.scopusqualityQ4en_US
dc.identifier.startpage281en_US
dc.identifier.urihttps://doi.org/10.5336/medsci.2023-96203
dc.identifier.urihttps://hdl.handle.net/20.500.14034/1648
dc.identifier.volume43en_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherTurkiye Kliniklerien_US
dc.relation.ispartofTurkiye Klinikleri Journal of Medical Sciencesen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectBevacizumab; epistaxis; hereditary hemorrhagic telangiectasiaen_US
dc.subjectbevacizumab; ferric carboxymaltose; hemoglobin; iron; Smad4 protein; adult; allergic rash; anemia; arthralgia; Article; bleeding; clinical article; cohort analysis; disease severity; disease severity assessment; epistaxis; erythrocyte transfusion; female; human; maintenance drug dose; male; middle aged; Rendu Osler Weber disease; retrospective study; scoring system; treatment duration; treatment responseen_US
dc.titleCourse of Treatment of Chronic Bleeding and Anemia with Systemic Bevacizumab Treatment in Hereditary Hemorrhagic Telangiectasia: A Retrospective Cohorten_US
dc.title.alternativeHerediter Hemorajik Telenjiyektazide Sistemik Bevasizumab Tedavisiyle Kronik Kanama ve Anemi Tedavisinin Seyri: Bir Retrospektif Kohorten_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
1648.pdf
Boyut:
605.45 KB
Biçim:
Adobe Portable Document Format
İndir

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu